IAN O A 70 Express Mail Label No. Dated:

MAINTENENTO 04 JAN 2005

Docket No.: 20241/0203472-US0

Examiner: Not Yet Assigned

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application	of:
Nobuhiro Umeda et al.	

Application No.: 10/552,015

7/552,015 Confirmation No.: N/A

Filed: October 11, 2005 Art Unit: N/A

For: DIAMINE DERIVATIVE, PRODUCTION

PROCESS THEREFOR AND

ANTIOXIDANT

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed within three months of the date of entry of the national stage of an international application as set forth in 37 CFR 1.491 (37 CFR 1.97(b)(2)).

Applicant submits herewith copies of foreign and non-patents in accordance with 37 CFR 1.98(a)(2).

A concise explanation of relevance of the items listed on form PTO/SB/08 is in pages 7 through 10 of the Specification and in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: January 4, 2006

Respectfully submitted,

Jav P. Lessler

Registration No.: 41,151 DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(212) 527-7719

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Su	Substitute for form 1449A/B/PTO			Complete if Known		
				Application Number	10/552,015	
	NFORMATION	N DI	SCLOSURE	Filing Date	October 11, 2005	
STATEMENT BY APPLICANT			APPLICANT	First Named Inventor	Nobuhiro Umeda	
				Art Unit	N/A	
	(Use as many sheets as necessary)		Examiner Name	Not Yet Assigned		
Sheet	1	of	2	Attorney Docket Number	20241/0203472-US0	

	U.S. PATENT DOCUMENTS					
Examiner	04-	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Initials*	Cite No. ¹	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	

		FOREI	GN PATENT	DOCUMENTS		\Box
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T [®]
	ВА	WO-01/14834A1	03-01-2001	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	ВВ	CA-2382418A1	03-01-2001	TAKEDA CHEMICAL INDUSTRIES, LTD.		
	ВС	WO-01/068610A1	09-20-2001	TAISHO PHARMACEUTICAL CO., LTD		
	BD	WO-03/022821A1	03-20-2003	TAISHO PHARMACEUTICAL CO., LTD.		
	BE	JP-8-503922	04-30-1996			\Box
	BF	WO-93/20057	10-14-1993	MERRELL DOW PHARMACEUTICALS INC.		
	BG	JP-5-140142	06-08-1993			
	ВН	EP-0483772A1	05-06-1992	TAKEDA CHEMICAL INDUSTRIES, LTD.		
·	BI	JP-5-310724	11-22-1993			\Box
	BJ	JP-2-288856	11-28-1990			П
	ВК	EP-0377450A1	07-11-1990	E.I. DU PONT DE NEMOURS AND COMPANY		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
	CA	SCOTT JOHN W., et al., "6-Hydroxychroman-2-carbioxylic Acids: Novel Antioxidants1" Journal of the American Oil Chemists' Society, Vol. 51, pp. 200-203.					
	СВ	CYRUS TILLMAN, et al., "Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice". The Journal of Clinical Investigation. June 1999, Vol. 103, Number 11, pp.1597-1604.					
	СС	ANDERSON RE, et al. "Free radicals and ocular disease", Adv. Exp. Med. Biol. 1994; 366: pp.73-86.					
	CD	NISHIGORI H. et al., "The alteration of lipid peroxide in glucocorticoid-induced cataract of developing chick embryos and the effect of the ascorbic acid.", Curr Eye Res. 1986 Jan;5(1); 37-40.					
	CE	HIRAMITSU T, et al. "Preventive effect of anitoxidants on lipid peroxidation in the retina.",					

Examiner	 	Date	
Signature	 	Considered	

PTO/SB/08a/b (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

7	Substitute for form 1449A/B/PTO				Complete if Known		
					Application Number	10/552,015	
	INFC	RMATIC	ON DISC	LOSURE	Filing Date	October 11, 2005	
ĺ	STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Nobuhiro Umeda	
					Art Unit	N/A	
	(Use as many sheets as necessary)			essary)	Examiner Name	Not Yet Assigned	
She	eet	2	of	2	Attorney Docket Number	20241/0203472-US0	

	Ophthalmic Res. 1991;23(4);196-203.
CF	Vitamin Information Center (Tokyo), VIC Newsletter, 105, 4, 2002.
CG	J. Act. Free Rad., Vol.3, No. 4, 1992, pp.444-449
СН	SOLBACH U, et al., "Imaging of retinal autofluorescence in patients with age-related macular degeneration.", Retina., 1997; 17(5): 385-389.
CI	Patent Abstracts of Japan for 2004-010513 published January 15, 2004.
C1	HARDER DR, "Role of cytochrome P-450 enzymes and metabolites of arachidonic acid in the control of vascular tone.", J Vasc Res. 1995 Mar-Apr; 32(2):79-92.
СК	MCGIFF JOHN C., et al., "20-HETE and the kidney: resolution of old problems and new beginnings.", Invited Review, the American Physiological Society, 1999, pp.R607-R623.
CL	ROMAN RICHARD J., "P -450 Metabolites of Archidonic Acid in the Control of Cardiovascular Function, Physiol Rev, Vol. 82, January 2002, pp.131-186.
СМ	C.D. FUNK, "Lipids and Lipid Metabolism", Biochimica et Biophysica Acta 1304, 1996, pp.65-84.
CN	ANDERSON ROBERT E. et al., "Free Radicals and Ocular Disease",pp. 73-86
СО	NISHIGORI HIDEO, et al., "The Alteration of Lipid Peroxide in Glucocorticoid-induced Cataract of Developing Chick Embryos and the Effect of Absorbic Acid.", Current Eye Res., Vol. 5, No.1, 1986, pp.37-40.
СР	TRUSCOTT R.J.W., et al., "The state of sulphydryl groups in normal and cataractous human lenses.", Exp. Eye Res., 1997, Vol. 25, 139-148.
CQ	HIRAMITSU TADAHISA, et al., "Preventive effect of antioxidants on lipid peroxidation in the retina.", Ophthalmic Res, 1991; Vol. 23; pp.196-203.
CR	SOLBACH UTA MD, et al., "Imaging of retinal autofluorescence in patients with age-related macular degeneration.", Retina, Journal of Retinal and Vitreous diseases, 1997, Vol. 17, No. 5, pp. 385-389.
CS	OHKAWA S., et al., "5-Aminocoumarans: Dual Inhibitors of Lipid Peroxidation and Dopamine Release with Protective Effects Against Central Nervous Sstem Trauma and Ischemia.", Journal of Med. Chem. 1997, Vol. 40, pp.559-573.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
	1
Signature	[Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.